Quarterly ResultJul 28, 2026, 07:06 AM
Incyte Q2 Revenue $1.67B (+38%); Raises FY26 Sales Guidance
AI Summary
Incyte reported strong second-quarter 2026 financial results, with total revenue increasing 38% to $1.67 billion and total net sales up 40% to $1.49 billion. This growth was significantly boosted by a $246 million non-cash benefit from a CMS settlement related to Opzelura. The company raised its full-year 2026 total net sales guidance to $5.13-$5.26 billion, reflecting strong product performance and the CMS agreement. Incyte also completed the acquisition of Vega Therapeutics for $1.25 billion, adding latarcibart to its pipeline, and expects ten clinical data readouts in the second half of 2026.
Key Highlights
- Total revenue increased 38% to $1.67 billion in Q2 2026.
- Total net sales rose 40% to $1.49 billion, including a $246 million Opzelura CMS benefit.
- Opzelura net sales grew 173% to $450 million in Q2 2026.
- Raised full-year 2026 total net sales guidance to $5.13-$5.26 billion.
- Acquired Vega Therapeutics for $1.25 billion upfront, adding latarcibart to pipeline.
- Increased full-year 2026 operating expense guidance due to acquisition.
- Jakafi XR received FDA approval for MF, PV, and GVHD.
- Monjuvi/Minjuvi global regulatory submissions for DLBCL accepted.
Price Impact
More from INCY